Comparing the current results to its competitors, Aprea Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 6.44 %, recorded in the same quarter.
Aprea Therapeutics Inc 's Comment on Competition and Industry Peers
The company is developing APR-1051, a selective WEE1 inhibitor distinguished by its molecular structure, selectivity, and a potentially lower risk of QT prolongation compared to competitor WEE1 inhibitors, which have been linked to significant toxicities and QT prolongation. The company has also developed ATRN-119 and ATRN-157, ATR inhibitors that demonstrated superior tumor growth inhibition and tolerability relative to a competitor ATR inhibitor in preclinical studies. Clinical data from oral ATR inhibitors BAY1895344, ART0380, and RP-3500 indicate synthetic lethality in certain cancers and show responses in tumors with specific mutations. The company operates in a highly competitive cancer drug sector that includes major pharmaceutical, specialty pharmaceutical, biotechnology companies, academic institutions, and governmental agencies. It faces competition from existing and emerging therapies, with many competitors possessing greater financial resources and expertise in development and commercialization.
December 11, 2024
Aprea Therapeutics Advances in Oncology: ATRN-119 Dual Dosing Approach and Promising Next-Gen Inhibitors Aprea Therapeutics, a prominent player in the field of oncology, has strategically advanced its clinical and research efforts by implementing innovative dosing strategies and unveiling significant updates on its promising drug pipeline. The company recently announced a shift to a twice-daily (BID) dosing regimen for patients in the ongoing ABOYA-119 clinical trial, in a bid to fully harness the therapeutic potential of its experimental drug, ATRN-119. Concurrently, Aprea s Safety Review Committee (SRC) has endorsed a notable single-dose strategy, maintaining 800 mg once daily dosing of ATRN-119, affirming...
October 10, 2024
In the ever-competitive healthcare sector, Aprea Therapeutics Inc finds itself at a pivotal moment. Recently, the company recorded a cumulative net loss of $13 million over the twelve months ending in the second quarter of 2024. This loss correlates with a negative return on investment (ROI) of -53.33%, placing Aprea in a challenging position, especially when compared to the 352 other companies in the healthcare sector that have reported higher ROI figures.Despite these financial hurdles, Aprea Therapeutics has shown noteworthy resilience. The company s overall ROI ranking, though still indicating a negative trajectory, has improved. As of the quarter ending June 30, 2024, Aprea s ROI ranking climbed to 2763...
June 17, 2024
In a recent development, Aprea Therapeutics, a clinical-stage biopharmaceutical company dedicated to precision oncology through synthetic lethality, announced the initiation of the ACESOT-1051 Phase 1 trial. The trial aims to evaluate the potential of their highly selective oral WEE1 inhibitor, APR-1051, as a cutting-edge treatment for Cyclin E-overexpressing cancers.First Patient Dosed in ACESOT-1051 Phase 1 Trial:A milestone moment for Aprea Therapeutics occurred with the dosing of the first patient in the ACESOT-1051 Phase 1 trial. This trial marks an essential step in testing the safety and efficacy of APR-1051, which has shown promise as a potentially best-in-class oral WEE1 inhibitor. The initiation of...
January 4, 2024
In the field of oncology, precision medicine has revolutionized the way cancer is diagnosed and treated. One promising area of research is synthetic lethality, which focuses on exploiting weaknesses in cancer cells that are dependent on specific genes or pathways for survival. Aprea Therapeutics, a clinical-stage biopharmaceutical company, is at the forefront of this innovation, with recent developments and ambitious plans for advancing its pipeline of DNA Damage Response (DDR) anti-cancer agents in 2024. This article provides an extensive analysis of Aprea Therapeutics corporate update and its potential impact on precision oncology.Corporate Update and Development Plans:Aprea Therapeutics recent corporate...
89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions.
Lixte Biotechnology Holdings Inc is a biotech company that focuses on the discovery and development of novel drugs for the treatment of cancer. They primarily operate by conducting pre-clinical and clinical studies, as well as collaborating with research institutions and pharmaceutical companies to advance their drug candidates.
Seres Therapeutics Inc focuses on the development and commercialization of microbiome-based therapeutics to treat serious diseases by harnessing the potential of the human microbiome.
Sources:
Aprea Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aprea Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
